Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
17.87
-0.53 (-2.88%)
At close: Dec 20, 2024, 4:00 PM
17.99
+0.12 (0.67%)
After-hours: Dec 20, 2024, 7:46 PM EST
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
105
Market Cap
13.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | 49.46K | 6.10% |
| Dec 31, 2019 | 810.55K | -56.28M | -98.58% |
| Jan 31, 2019 | Pro | Pro | Pro |
| Jan 31, 2018 | Pro | Pro | Pro |
| Jan 31, 2017 | Pro | Pro | Pro |
| Jan 31, 2016 | Pro | Pro | Pro |
| Jan 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fresenius Medical Care AG | 21.46B |
| DaVita | 12.67B |
| Avantor | 6.82B |
| Incyte | 4.08B |
| Dr. Reddy's Laboratories | 3.58B |
| Genmab | 2.97B |
| BioMarin Pharmaceutical | 2.75B |
| Revvity | 2.72B |
SMMT News
- 8 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 19 days ago - Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial - Seeking Alpha
- 25 days ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Benzinga
- 7 weeks ago - Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 - Business Wire
- 2 months ago - Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 - Business Wire
- 2 months ago - Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track - Investopedia